Is MRD eradication a desirable goal in CLL?

Best Practice & Research. Clinical Haematology
Carol MorenoAndy Rawstron

Abstract

Among chronic lymphocytic leukaemia (CLL) patients who require therapy, their response to therapy is the most important prognostic factor, with a better response predicting longer progression-free and overall survival. In this context, patients who achieve minimal residual disease (MRD)-negative status have better prognosis than those with inferior response to therapy, including those with MRD-positive complete response (CR). MRD can be assessed by either allele-specific polymerase chain reaction (PCR) or four-colour cytofluorometry. Importantly, methods to determine MRD in CLL have been standardised. Nevertheless, MRD status should not be used as a goal of therapy outside clinical studies. This is because the issue of the benefits of achieving MRD-negative status in patients with CLL requires further investigation in large controlled trials, in which patients should be stratified according to not only clinical variables but also biological parameters such as cytogenetics, IGHV mutations or ZAP-70 expression.

References

Jun 12, 2002·Bone Marrow Transplantation·K C DoneyUNKNOWN Seattle Bone Marrow Transplant Team
Sep 14, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Vicki A MorrisonCharles A Schiffer
Oct 23, 2002·The Hematology Journal : the Official Journal of the European Haematology Association·Tadeusz RobakDariusz Wołowiec
Dec 11, 2002·British Journal of Haematology·Francesc BoschUNKNOWN GELCAB (Grup per l'Estudi dels Limfomes a Catalunya i Balears)
Jul 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J ScheteligUNKNOWN Cooperative German Transplant Study Group
Mar 2, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Emili Montserrat
Mar 2, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paul MoretonPeter Hillmen
Mar 16, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William WierdaMichael Keating
Mar 16, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael J KeatingHagop Kantarjian
Apr 6, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mohamed L SorrorDavid G Maloney
Apr 19, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marco MontilloEnrica Morra
Oct 11, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H GogasE T Petridou
Nov 7, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter HillmenJiri Mayer
Jan 4, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Francesc BoschEmili Montserrat
Sep 17, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mohamed L SorrorDavid G Maloney
Aug 26, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Francesc BoschEmili Montserrat

❮ Previous
Next ❯

Citations

Dec 14, 2011·Proceedings of the National Academy of Sciences of the United States of America·Aaron C LoganDavid B Miklos
Feb 15, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sebastian BöttcherMichael Kneba

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.